74 results about "Colorectal tumor" patented technology

A33 antigen binding proteins are described for use in the diagnosis or treatment of colorectal tumors and metastases arising therefrom. The binding protein may be a humanized A33 antibody, including complete antibody molecules, fragments thereof, and particularly, multivalent monospecific proteins comprising two, three, four or more antibodies or fragments thereof, bound to each other by a cross-linking agent. For diagnosis or therapy, the humanized A33 antibody may be linked to a reporter or effector molecule.

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long DNA (e.g., quantified by Alu PCR) and the presence and level of tumor-associated gene alterations (e.g., mutations in KRAS, APC, melanoma antigen gene, p53, BRAF, BAT26, PIK3CA) or epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of bmp-3, bmp-4, SFRP2, vimentin, septin9, ALX4, EYA4, TFPI2, NDRG4, FOXE1) in DNA from a stool sample obtained from the mammal.

The invention provides a primer and a probe for detecting methylation levels of BMP3 and NDRG4 in a biological sample and further provides a method and a kit for detecting the methylation levels of BMP3 and NDRG4 in the biological sample by virtue of the primer and the probe. The primer and the probe have high sensitivity and specificity; by virtue of the detection method, early diagnosis information of colorectal tumors can be provided, and a simple, convenient and feasible solution is provided for the early detection of the colorectal tumors.

A unique transcription product, CRCA-1, and alternative translation products generated therefrom, are disclosed. The transcript and its translation products are markers for colorectal cells. Screening and diagnostic reagents, kits and methods for metastasized colorectal cancer are disclosed as are reagents, kits and methods for identifying adenocarcinomas as colorectal in origin. Compounds, compositions and methods of treating patients with metastasized colorectal cancer and for imaging metastasized colorectal tumors in vivo are disclosed. Compositions and methods for delivering active compounds such as gene therapeutics and antisense compounds to colorectal cells are disclosed. Vaccines compositions and methods of for treating and preventing metastasized colorectal cancer are disclosed.

In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of colorectal cancer cells and be used as a pharmaceutical composition to inhibit the colorectal tumor growth.

In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.

A traditional Chinese medicine composition preventing and treating colorectal precancerous lesion, a preparing method thereof and applications of the composition are disclosed. The composition includes 20-60 parts of hedyotis, 9-27 parts of lightyellow sophora root, 15-45 parts of radix codonopsis, 12-36 parts of largehead atractylodes rhizome, 12-36 parts of smoked plum, 3-9 parts of rhizoma coptidis, 6-18 parts of rhizoma zingiberis praeparatum and 30-90 parts of coix seed. Prescription screening is performed according to a traditional Chinese medicine theory that is treatment based on syndrome differentiation and according to pathogenesis of intestinal cancer. Treatment mechanisms of invigorating the spleen, benefiting qi, removing heat, drying dampness, detoxifying, removing stasis, and strengthening and consolidating body resistance are adopted innovatively. Experiment results show that the composition can obviously improve AOM-DSS induced symptoms such as body mass decrease, loose stool, and hemafecia, that the composition can reduce the occurrence rate of a colorectal lesion that is mouse colon tumor, and that the composition has significant activity resisting solid colorectal tumor and intestine cytoma. Disassembled prescription experiment results show that medicine materials of the composition are irreplaceable and the composition is a scientific prescription.

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.

Nucleic acids and proteins that are overexpressed in colon or colorectal tumor tissues, and which are useful diagnostic and therapeutic targets.

The invention relates to the field of gene detection and bioinformatics. The invention discloses an application of a complex disease state evaluation method constructed based on high-throughput sequencing data and clinical phenotypes in a colorectal tumor state evaluation model. The invention discloses a method for mining colorectal cancer markers based on transcriptome data, exon group / genome data and clinical phenotypes. The invention designs a set of calculation method for constructing a colorectal cancer state evaluation model by integrating high-throughput sequencing data and clinical phenotypes, biomarkers related to colorectal cancer are screened out, and a corresponding disease state evaluation model is formed. The markers considering both accuracy and mechanism interpretability are constructed through the method and can be used for colorectal cancer prognosis evaluation, treatment effect prediction, treatment scheme assistant decision making and the like.

A unique transcription product, CRCA-1, and alternative translation products generated therefrom, are disclosed. The transcript and its translation products are markers for colorectal cells. Screening and diagnostic reagents, kits and methods for metastasized colorectal cancer are disclosed ars are reagents, kits and methods for identifying adenocarcinomas as colorectal in origin. Compounds, compositions and methods of treating patients with metastasized colorectal cancer and for imaging metastasized colorectal tumors in vivo are disclosed. Compositions and methods for delivering active compounds such as gene therapeutics and antisense compounds to colorectal cells are disclosed. Vaccines compositions and methods of for treating and preventing metastasized colorectal cancer are disclosed.

The invention discloses an application of FGF21 in preparation of a medicine for treating colorectal cancer, and belongs to the technical field of medicines. The FGF21 protein provided by the invention is a secretory protein composed of about 210 amino acids. The invention finds for the first time that the FGF21 has the effect of treating colorectal tumor, and cytological experiments and animal experiments prove that the FGF21 can inhibit proliferation, invasion and migration of a colorectal tumor cell line, and can obviously reduce the size of a tumor focus in a mouse model. The medicine which is used for treating colorectal cancer and is prepared by taking the FGF21 as an active substance has the effects of being good in safety, long in medicine effect lasting time, capable of protectingorgans from being damaged and capable of improving lipid metabolism disorder.

The present invention relates to methods and kits for the detection of predetermined biomarkers for early diagnosis and management of cancer, and in particular, colorectal tumors.

In vi tro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.

The invention relates to methods of determining a colorectal tumor stage in a patient by gene expression analysis. The method comprises assaying the level of at least one RNA transcript, or its expression product, which is correlated to colorectal tumor stage. The invention may be useful for determining whether a patient has stage II or stage III colorectal cancer.

A method for dynamic contrast enhanced (DCE) image processing and kinetic modeling of an organ's region-of-interest is provided. The method includes deriving at least a contour of an exterior of the organ's region-of-interest from one or more of a plurality of images; generating a spline function in response to the derived contour of the exterior of the organ's region-of-interest from the one or more of the plurality of images; registering the plurality of images wherein the organ's region-of-interest has been segmented; deriving a tracer curve for the organ's region-of-interest in the registered images, the tracer curve indicating a change in concentration of a contrast agent flowing through the organ's region-of-interest over a time period; and kinetic modeling by fitting a kinetic model to the tracer curve to generate one or more maps of tissue physiological parameters associated with the kinetic model.

The invention relates to application of miR-24-1-5p to colorectal tumor. An expression condition of the miR-24-1-5p in a colorectal tumor tissue and five types of colorectal tumor cell lines is detected by fluorescent quantitative PCR (Polymerase Chain Reaction) and a result finds out that the expression of the miR-24-1-5p in the colorectal tumor tissue and cells is obviously regulated downwards and the miR-24-1-5p plays an important regulation and control role in occurring and development processes of the colorectal tumor. By constructing an miR-24-1-5p overexpression carrier, a colorectal tumor cell Caco2 and HCT-116 cells are transfected, and MTT (Methyl Thiazolyl Tetrazolium), cell scratch, Transwell and plate cloning experiments are used for researching influences of the miR-24-1-5p on proliferation and migration of the colorectal tumor cells; results show that the miR-24-1-5p can be used for remarkably inhibiting the proliferation and the migration of the colorectal tumor cells and can be used for a biological preparation for treating the colorectal tumor.

The present invention relates to nucleic acid sequences which are overexpressed in colorectal tumors which display a high level of microsatellite instability (MSI-H) vs. tumors displaying a low level of microsatellite instability (MSS), and can thus be used to identify MSI-H in a patient, and be used further to facilitate patient prognosis, monitor disease progression / regression, identify appropriate treatment regimes, and evaluate the efficacy of treatment.

The invention discloses a novel purpose of a DNA binding site CTCF_113 of a multifunctional transcriptional regulatory factor CTCF, i.e., the application thereof to prevention of a kit for early diagnosis of colorectal carcinoma. The binding site has the nucleotide sequence shown as SEQ ID NO:1. The accuracy of the CTCT binding site provided by the invention for detecting rectal adenoma and colorectal cancer is obviously higher than that of the reported DNA methylation molecular markers; the DNA binding site of the CTCF can be likely to become a biomarker for tumor treatment effect monitoring, prognosis effect evaluation and tumor molecular subtyping (such as CIMP subtyping). Generally, the invention provides a novel idea for finding the more effective tumor early stage diagnosis, treatment effect monitoring, prognosis effect evaluation and molecular subtyping molecular markers, and has the important significance on tumor prevention and treatment.

The invention relates to a preparation method and an application of a graphene-CpG. The preparation method is characterized by specifically comprising the steps of functionalizing the graphene, weighing 1mg of graphene and 5mg of PL-PEG5000-Amine (Biotin-Poly Ethylene Glycol) or PL-PEG2000-Amine and adding the two materials to a 20ml straight thick-wall glass tube, adding 5ml of distilled water to the 20ml straight thick-wall glass tube and putting the 20ml straight thick-wall glass tube in a shaker for shaking until DSPE-PEG (Distearoyl Phosphatidyl Ethanolamine-Poly Ethylene Glycol) is completely dissolved; centrifuging a graphene suspension at the room temperature for 3 hours at a rotating speed of 24000g and collecting the supernate, and recording the UV-VIS-NIR (Ultraviolet-Visual-Near Infrared) absorption spectrum of the obtained graphene solution, wherein the final concentration of the graphene is in a normal rang of 40-70mg / L; and preserving at 4 DEG C, and then bonding the graphene with an oligonucleotide CpG. The preparation method is unique and capable of obviously inhibiting the growth of the tumor of breast and the tumor of colorectum; compared with a PBS (Phosphate Buffer Solution) group, the graphene-CpG prepared by the preparation method disclosed by the invention has the advantages that the difference is significant and the growth of the tumors is obviously suppressed; besides, the preparation method has statistical significance.

The invention relates to the technical field of biological medicines, in particular to a method for detecting and identifying subspecies of fusobacterium nucleatum. The fusobacterium nucleatum is closely associated with various diseases, and recent research shows that the fusobacterium nucleatum can promote generation and development of colorectal tumors. However, an accurate and visual detection method for distinguishing different subspecies of the fusobacterium nucleatum is lacked at present. Different subspecies of the fusobacterium nucleatum are different in biological characteristic, colonization and pathogenicity, so that accurate subspecies identification has far-reaching significance for knowing the pathogenic mechanism of the fusobacterium nucleatum. According to the invention, a group of specific DNA sequences for identifying the fusobacterium nucleatum subspecies are provided, corresponding detection primers are designed, and the application of the detection primers in subspecies level detection and identification of the fusobacterium nucleatum is explained. According to the invention, the composition and the source of the subspecies of the fusobacterium nucleatum in the focus can be disclosed, and the relationship between different subspecies and diseases and related epidemiological characteristics can be explored.

The invention discloses a tumor marker related to colorectal cancer and application. The tumor marker is lncRNA (long noncoding RNA) and is located on the seventeenth chromosome of chr17: 47785696-47797422, a nucleotide sequence of the lncRNA is shown in SEQ ID NO.1 is named as lncRNA-KAT7. According to the lncRNA-KAT7 sequence, specific real-time fluorescent quantitative PCR primer can be designed and synthesized to be used for preparing preparation for colorectal cancer diagnosis or treating effect prediction. By means of the real-time fluorescent quantitative PCR preparation, expression level of lncRNA-KAT7 is detected in colorectal cancer clinical case specimen, expression of the lncRNA-KAT7 in the colorectal cancer is found to be obviously reduced, the lncRNA-KAT7 has obvious statistic significance (p<0.05), and low expression of the lncRNA-KAT7 in the colorectal cancer is closely related to colorectal tumor differentiation, T staging, invasion and metastasis. The result shows that the lncRNA-KAT7 can serve as the tumor marker of the colorectal cancer and can be used for preparing preparation or kits applied to auxiliary diagnosis, treating effect prediction and prognosis of the colorectal cancer.

The invention relates to a diagnostic marker for early colorectal cancer, wherein the diagnostic marker is circular RNA circ3823, and the nucleotide sequence of the diagnostic marker is shown in SEQ ID No.1; and an application of the circular RNA circ3823 in preparing a diagnostic tool for early colorectal cancer, wherein the tool is a kit, and the tool comprises a primer pair for amplifying a nucleic acid sequence for specifically recognizing the circular RNA circ3823. The marker can clearly and clearly characterize the occurrence of early colorectal tumor diseases, the expression of the marker in a plurality of early CRC tissue samples is significantly higher than that in a control tissue samples (normal tissues which are 5cm away from tumor tissues), and the expression of the marker ina plurality of early CRC patient serum samples is significantly higher than that in a control healthy serum sample.

The invention discloses an application of indacaterol in the treatment of colorectal cancer, and belongs to the field of molecular biology, in particular, tumor treatment. Specifically, indacaterol selected from disclosed drugs can treat colorectal cancer. The results of cell experiments and animal experiments show that indacaterol can inhibit the proliferation, invasion and migration of colorectal tumor cell lines, and can obviously reduce the size of colorectal tumors of a mouse model. At the same time, for the first time, people find that indacaterol corrects the alternative splicing of tumor cells to achieve the effects mentioned above.

The invention provides a method and system for determining colorectal tumor cells on the basis of KRAS and NDRG4 genes. The method includes: acquiring the KRAS gene and NDRG4 gene of a to-be-determined sample, and performing methylation on the NDRG4 gene; sequencing the KRAS gene and the NDRG4 gene after the methylation to obtain a KRAS gene sequencing result and a NDRG4 gene sequencing result; performing first comparison on the gene sequence of a first target position in the KRAS gene sequencing result and first reference sequence to calculate KRAS gene mutation rate; performing second comparison on the gene sequence of a second target position in the NDRG4 gene sequencing result and second reference sequence to calculate NDRG4 gene methylation linkage rate; determining whether the to-be-determined sample has colorectal tumor cells or not according to the KRAS gene mutation rate and the NDRG4 gene methylation linkage rate. By the method and system high in sensitivity, whether the sample has the colorectal tumor cells or not can be determined fast, simply and specifically.

The invention provides Zyxin gene shRNA inhibiting tumor cell proliferation and migration, a recombinant vector and application, and particularly relates to shRNA specifically silencing a Zyxin (ZYX)gene. A silencing vector of the Zyxin gene is constructed. A shRNA fragment is designed first based on the human Zyxin gene sequence, the synthesized fragment has suitable restriction sites at both ends, and the target fragment is connected to a lentiviral vector to form the core silencing vector. The constructed shRNA vector can significantly inhibit the expression of the Zyxin gene at the protein level. Furthermore, a lentivirus is used as a vector carrying shRNA, and the vector can introduce the shRNA sequence directed at the Zyxin gene into colorectal tumor cells in a targeted manner and significantly inhibit the proliferation and migration capability of the colorectal tumor cells.

Immune context scores are calculated for stage IV colorectal tumor tissue samples using non-continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a density of human CD8+ cells in a region of interest including a tumor core to generate an immune context score. The immune context score can then be used as a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and / or treatment decisions.

The invention belongs to the technical field of biological medicine, and provides a colorectum-targeted drug-loaded exosome and application thereof, and a medicine for treating colorectal diseases. The colorectum-targeted drug-loaded exosome is obtained by introducing the medicine for treating the colorectal diseases into an exosome with a colorectal tissue targeting property; and the exosome with colorectal tissue targeting property is derived from lung cells. A colorectal tumor treatment drug contains the colorectum-targeted drug-loading exosome. Compared with the prior art, the exosome secreted by the lung cells can be enriched in the colorectum without any modification, the exosome derived from the lung cells is used, the problem of exosome yield is solved, and good application prospect is obtained; and different drugs or active molecules can be loaded by using the lung cell-derived exosome, and the treatment effect of colorectal diseases is improved and toxic and side effects of the drugs are reduced through targeted colorectal tissue administration.

Hypermethylation of the SPARC promoter is identified as a mechanism for repressing SPARC gene in cancer resulting in resistance to therapy. The restoration of SPARC expression with demethylating agents, such as 5-Aza-2′deoxycytidine, is shown to enhance chemosensitivity. The invention provides a mechanism of limiting the number of patients exposed to toxicity of demethylating agents by targeting its administration to the subset of patients with hypermethylation of the SPARC promoter.